Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cryoablation with Tislelizumab and Bevacizumab for PD-1/L1-Resistant HCC
NCT06530784Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, bevacizumab in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
tislelizumabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06530784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530784.